---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268102"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:37:22.504833+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics Q3 2025 net loss $21M; divesiran Phase 2 fully enrolled with topline data in 3Q 2026

## Summary
- Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.
- Net loss $21.0M for Q3 2025 vs $35.5M in Q3 2024, primarily due to lower foreign currency loss.
- SANRECO Phase 2 study of divesiran in polycythemia vera fully enrolled (48 patients); topline results expected Q3 2026.
- R&D expenses $20.5M (vs $20.2M YoY); G&A expenses $5.8M (vs $7.7M YoY).

## SEC filing metadata
- accession: 0001193125-25-268102
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/0001193125-25-268102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268102
- JSON: https://secwatch.observer/filing/0001193125-25-268102.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.